Hanall Biopharma Co., Ltd. (KRX:009420)
South Korea
· Delayed Price · Currency is KRW 49,500
-2,000 (-3.88%)
Apr 29, 2026, 3:30 PM KST
Hanall Biopharma Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -5,559 | -1,805 | 3,509 | 251.47 | 8,896 | Upgrade
|
| Depreciation & Amortization | 3,561 | 3,121 | 3,247 | 3,053 | 2,725 | Upgrade
|
| Loss (Gain) From Sale of Assets | -23.18 | 452.56 | 9.32 | -16.99 | 1,052 | Upgrade
|
| Asset Writedown & Restructuring Costs | 264.6 | - | 36.72 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 4,182 | -178.46 | -1,121 | 625.15 | 177.44 | Upgrade
|
| Loss (Gain) on Equity Investments | 157.66 | -53.45 | 62.12 | 45.39 | - | Upgrade
|
| Stock-Based Compensation | 340.68 | 584.26 | 1,623 | 1,875 | 1,617 | Upgrade
|
| Provision & Write-off of Bad Debts | -0.29 | -126.7 | 50.6 | 61.23 | -21.9 | Upgrade
|
| Other Operating Activities | 4,207 | 3,819 | 2,044 | 4,516 | 1,694 | Upgrade
|
| Change in Accounts Receivable | 1,244 | 2,367 | 8,168 | -2,466 | -5,919 | Upgrade
|
| Change in Inventory | -2,233 | -5,748 | -8,292 | -5,814 | -1,476 | Upgrade
|
| Change in Accounts Payable | -2,492 | -127.23 | 5,518 | 3,361 | -1,731 | Upgrade
|
| Change in Other Net Operating Assets | -5,990 | 7,055 | 14,789 | 19,774 | -6,174 | Upgrade
|
| Operating Cash Flow | -2,340 | 9,360 | 29,643 | 25,264 | 839.87 | Upgrade
|
| Operating Cash Flow Growth | - | -68.42% | 17.33% | 2908.10% | -9.62% | Upgrade
|
| Capital Expenditures | -948 | -1,642 | -2,412 | -2,830 | -4,606 | Upgrade
|
| Sale of Property, Plant & Equipment | 23.93 | - | - | 17 | 120.91 | Upgrade
|
| Sale (Purchase) of Intangibles | -13,168 | -21,427 | -6,786 | -4,847 | -4,396 | Upgrade
|
| Investment in Securities | -5,145 | -4,129 | -2,676 | -2,932 | 16,911 | Upgrade
|
| Other Investing Activities | 199.46 | -0 | -0 | - | -0 | Upgrade
|
| Investing Cash Flow | -18,832 | -27,493 | -11,887 | -10,592 | 8,030 | Upgrade
|
| Short-Term Debt Issued | 15,894 | - | - | - | - | Upgrade
|
| Long-Term Debt Issued | 15,000 | - | - | - | - | Upgrade
|
| Total Debt Issued | 30,894 | - | - | - | - | Upgrade
|
| Long-Term Debt Repaid | -993.86 | -942.18 | -813.51 | -698.88 | -715.25 | Upgrade
|
| Total Debt Repaid | -993.86 | -942.18 | -813.51 | -698.88 | -715.25 | Upgrade
|
| Net Debt Issued (Repaid) | 29,900 | -942.18 | -813.51 | -698.88 | -715.25 | Upgrade
|
| Issuance of Common Stock | 2,887 | 1,702 | - | - | 408.72 | Upgrade
|
| Repurchase of Common Stock | -3,221 | - | - | -10,005 | - | Upgrade
|
| Financing Cash Flow | 29,566 | 759.59 | -813.51 | -10,704 | -306.53 | Upgrade
|
| Foreign Exchange Rate Adjustments | -37.2 | 36.83 | -60.45 | 78.63 | 30.85 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | -0 | 0 | 0 | - | - | Upgrade
|
| Net Cash Flow | 8,357 | -17,336 | 16,882 | 4,047 | 8,594 | Upgrade
|
| Free Cash Flow | -3,288 | 7,718 | 27,231 | 22,434 | -3,766 | Upgrade
|
| Free Cash Flow Growth | - | -71.66% | 21.38% | - | - | Upgrade
|
| Free Cash Flow Margin | -2.12% | 5.56% | 20.18% | 20.39% | -3.71% | Upgrade
|
| Free Cash Flow Per Share | -64.76 | 152.20 | 537.18 | 441.48 | -73.55 | Upgrade
|
| Cash Interest Paid | 133.93 | 70.97 | 63.86 | 39.45 | - | Upgrade
|
| Cash Income Tax Paid | -214.79 | 782.26 | 1,017 | 606.84 | 1,695 | Upgrade
|
| Levered Free Cash Flow | -16,971 | -26,378 | 4,850 | -17,027 | -665.94 | Upgrade
|
| Unlevered Free Cash Flow | -16,882 | -26,333 | 4,890 | -17,014 | -650.01 | Upgrade
|
| Change in Working Capital | -9,471 | 3,548 | 20,183 | 14,855 | -15,299 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.